Use of psychotropic drugs in the treatment of fibromyalgia: a systematic review


  • Ana Vívian Ferreira da Costa Médica pela Faculdade de Medicina Estácio de Juazeiro do Norte- FMJ, Brasil, Rua Tenente Raimundo Rocha, 515- 63048080, Juazeiro do NorteCE- Brasil
  • Larissa de Carvalho Bezerra Acadêmica do curso de Medicina da Faculdade de Medicina Estácio de Juazeiro do Norte- CE, Brasil, Rua Tenente Raimundo Rocha, 515- 63048080, Juazeiro do NorteCE- Brasil
  • Juliane dos Anjos de Paula Mestrado em ciências da saúde pela faculdade de Medicina do ABC, Residência Médica em Psiquiatria no Hospital das Clínicas da UFPE, Professora do curso de medicina na disciplina de saúde mental da Faculdade de Medicina Estácio de Juazeiro do Norte –FMJ, Brasil, Rua Professora Maria Nilde Couto Bem -220- Triângulo- 63041155- Juazeiro do Norte- CE- Brasil



Fibromyalgia , Psychotropics , Treatment Outcome


Introduction: The treatment of fibromyalgia is evolving, and more and more drugs are available on the market.

Objective: To verify the response, tolerability, and adverse events of the use of psychotropic drugs in the treatment of fibromyalgia.

Methods: A systematic review of articles on fibromyalgia and psychotropic medications were carried out, indexed in the MEDLINE database (PUBMED) with the MeSH terms: “fibromyalgia”, “psychotropic drugs,” and “treatment outcome”. Of the 89 studies identified, 23 met the eligibility criteria.

Results: It has been seen that some classes of psychotropic medications have significantly improved patients' painful episodes, which have an important positive impact on quality of life. Thus, it was realized that the pharmacological treatment of psychiatric disorders associated with fibromyalgia improves the condition of the patient's acceptance of the disease. Most medications had a good impact on the patient's quality of life without major side effects. It is known that adverse events are proportional to the dose of psychotropics, so for each patient, it is necessary to individualize the conduct.

Conclusion: Antidepressants were the best-tolerated drug class, but antipsychotics, anticonvulsants, and other more recent drugs such as agomelatine were part of the study of the main drugs used in clinical practice.


Download data is not yet available.


Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, et al. Segurança a longo prazo, tolerabilidade e eficácia da duloxetina no tratamento da fibromialgia. Seminários em Artrite e Reumatismo. junho de 2010; 39(6): 454-64

Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. dezembro de 2005; 119 (1–3): 5–15

Samborski W, Lezańska-Szpera M, Rybakowski JK. Effects of antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst. 2004; 49:265–9.

Bruno A, Micò U, Lorusso S, Cogliandro N, Pandolfo G, Caminiti M, et al. Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. Journal of Clinical Psychopharmacology. agosto de 2013; 33 (4): 507–11.

A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol. 2015; 33 (1 Suppl 88).

Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. Pain Physician. outubro de 2013; 16 (5): E553-562.

Potvin S, Morin M, Cloutier C, Gendron A, Bissonnette A, Marchand S. Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. Journal of Clinical Psychopharmacology. outubro de 2012; 32 (5): 684–7.

Jensen KB, Petzke F, Carville S, Choy E, Fransson P, Gracely RH, et al. Segregating the cerebral mechanisms of antidepressants and placebo in fibromyalgia. The Journal of Pain. dezembro de 2014; 15 (12): 1328–37.

Arnold LM, Palmer RH, Gendreau RM, Chen W. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran. Psychosomatics. julho de 2012; 53 (4): 371–9.

Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011; 13 (3): R86.

García-Campayo J, Serrano-Blanco A, Rodero B, Magallón R, Alda M, Andrés E, et al. Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. Trials. dezembro de 2009; 10 (1): 24.

Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. outubro de 2005; 32 (10): 1975–85.

McIntyre A, Paisley D, Kouassi E, Gendron A. Quetiapine fumarate extended-release for the treatment of major depression with comorbid fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study: quetiapine xr for patients with mdd and fibromyalgia. Arthritis & Rheumatology. fevereiro de 2014; 66 (2): 451–61.

Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - Individual patient data responder analysis. European Journal of Pain (United Kingdom) [Internet]. 2014 Jan [cited 2021 May 24]; 18(1): 67–75. Available from:

A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures-PubMed [Internet]. [cited 2021 May 24]. Available from:

Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care and Research [Internet]. 2013 Nov [cited 2021 May 24]; 65(11): 1813–9. Available: from:

[Tratamento da fibromialgia] - PubMed [Internet].[cited 2021 May 24]. Available from:

Rivera J, Vallejo MÁ, Esteve-Vives J, Alegre C, Belenguer R, Belmonte M, et al. Estrategias de prescripción de fármacos en el tratamiento de pacientes con fibromialgia. Reumatologia Clinica [Internet]. 2012 Jul [cited 2021 May 24];8(4):184–8. Available from:

Freedenfeld RN, Murray M, Fuchs PN, Kiser RS. Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic. Pain Practice [Internet]. 2006 Jun [cited 2021 May 24]; 6(2): 112–8. Available from:

Calandre EP, Morillas-Arques P, Molina-Barea R, Rodriguez-Lopez CM, Rico-Villademoros F. Trazodone plus pregabalin combination in the treatment of fibromyalgia: A two-phase, 24-week, open-label uncontrolled study. BMC Musculoskeletal Disorders [Internet]. 2011 [cited 2021 May 24];12. Available from:

Calandre EP, Rico-Villademoros F, Galán J, Molina-Barea R, Vilchez JS, Rodriguez-Lopez CM, et al. Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: A 16-week, randomized, flexible-dose, open-label trial. Psychopharmacology [Internet]. 2014 [cited 2021 May 24]; 231(12): 2525–31. Available from:

Dwight MM, Arnold LM, O’Brien H, Metzger R, Morris-Park E, Keck PE. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics [Internet]. 1998 [cited 2021 May 24];39(1):14–7. Available from:

Rico-Villademoros F, Rodriguez-Lopez CM, Morillas-Arques P, Vilchez JS, Hidalgo J, Calandre EP. Amisulpride in the treatment of fibromyalgia: An uncontrolled study. Clinical Rheumatology [Internet]. 2012 Sep [cited 2021 May 24]; 31(9): 1371–5. Available from: